Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis - PubMed (original) (raw)

Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis

W Paxton et al. J Virol. 1993 Dec.

Abstract

The product of the vpr open reading frame of human immunodeficiency virus type 1 (HIV-1) is a 15-kDa, arginine-rich protein that is present in virions in molar quantities equivalent to that of Gag. We report here the results of our investigations into the mechanism by which Vpr is incorporated into virions during assembly in infected cells. For these studies we used an expression vector encoding a Vpr molecule fused at its amino terminus to a nine-amino-acid peptide from influenza virus hemagglutinin. The tagged Vpr expression vector and a vpr mutant HIV-1 provirus were used to cotransfect COS cells, and the resulting virions were tested for the presence of the tagged protein on immunoblots probed with monoclonal antibody against the hemagglutinin peptide. The COS-produced virions were found to contain readily detectable amounts of tagged Vpr and smaller amounts of a putative tagged Vpr dimer. Infectivity of the particles was not altered by incorporation of tagged Vpr. Our results using this system in combination with mutant HIV-1 proviruses suggested that incorporation of Vpr into virions requires the carboxy-terminal Gag protein of HIV-1 (p6) but not gp160, Pol, or genomic viral RNA. In addition, analysis of mutated, tagged Vpr molecules suggested that amino acids near the carboxy terminus (amino acids 84 to 94) are required for incorporation of Vpr into HIV-1 virions. The single cysteine residue near the carboxy terminus was required for production of a stable protein. Arginine residues tested were not important for incorporation or stability of tagged Vpr. These results suggested a novel strategy for blocking HIV-1 replication.

PubMed Disclaimer

Cited by

Vpr Is a VIP: HIV Vpr and Infected Macrophages Promote Viral Pathogenesis.
Lubow J, Collins KL. Lubow J, et al. Viruses. 2020 Jul 27;12(8):809. doi: 10.3390/v12080809. Viruses. 2020. PMID: 32726944 Free PMC article. Review.
Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.
Schröfelbauer B, Yu Q, Zeitlin SG, Landau NR. Schröfelbauer B, et al. J Virol. 2005 Sep;79(17):10978-87. doi: 10.1128/JVI.79.17.10978-10987.2005. J Virol. 2005. PMID: 16103149 Free PMC article.
Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr?
Ayinde D, Maudet C, Transy C, Margottin-Goguet F. Ayinde D, et al. Retrovirology. 2010 Apr 9;7:35. doi: 10.1186/1742-4690-7-35. Retrovirology. 2010. PMID: 20380700 Free PMC article. Review.
Nuclear export of Vpr is required for efficient replication of human immunodeficiency virus type 1 in tissue macrophages.
Sherman MP, de Noronha CM, Eckstein LA, Hataye J, Mundt P, Williams SA, Neidleman JA, Goldsmith MA, Greene WC. Sherman MP, et al. J Virol. 2003 Jul;77(13):7582-9. doi: 10.1128/jvi.77.13.7582-7589.2003. J Virol. 2003. PMID: 12805458 Free PMC article.
Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.
Accola MA, Strack B, Göttlinger HG. Accola MA, et al. J Virol. 2000 Jun;74(12):5395-402. doi: 10.1128/jvi.74.12.5395-5402.2000. J Virol. 2000. PMID: 10823843 Free PMC article.

References

1. J Virol. 1990 Jun;64(6):3097-9 - PubMed
1. J Virol. 1990 Jun;64(6):2743-50 - PubMed
1. J Virol. 1990 Oct;64(10):5230-4 - PubMed
1. J Virol. 1990 Nov;64(11):5688-93 - PubMed
1. Proc Natl Acad Sci U S A. 1990 Oct;87(20):8080-4 - PubMed

Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis - PubMed (original) (raw)